Acer Therapeutics' Reverse Merger Round

Acer Therapeutics raised a round of funding on September 20, 2017. Investors include Opexa Therapeutics.

Acer Therapeutics is developing the first pharmaceutical therapy for patients with Maple Syrup Urine Disease (MSUD). MSUD is a devastating genetic disease – an inborn error of amino acid metabolism.…

Articles about Acer Therapeutics' Reverse Merger Round: